Close Menu

NEW YORK ─ The US Food and Drug Administration on Thursday granted Emergency Use Authorization to Luminex for its xMap SARS-CoV-2 Multi-Antigen IgG Assay, which detects IgG antibodies against SARS-CoV-2 on the Luminex 200, Magpix, Magpix NxTag-enabled, and Flexmap 3D systems.

In afternoon trading on the Nasdaq Friday, Luminex shares rose more than 7 percent on the news to $37.11 and dropped to $36.28 at the close of trading.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.